Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Pantoro is pleased to confirm advanced discussions with Tulla Resources Plc ( ASX:TUL ) (Tulla ) for the consolidation of the Norseman Gold Project into a single entity, with both parties negotiating to complete a binding term sheet.
Norseman to be the major focus for Pantoro going forward with other assets to be exited or capital spend reduced.
Operational review complete and capital development to be suspended pending improvement in market operating
A 30-hole, 2,290m RC drilling program has been completed at the Kambale Graphite project, Ghana.
The drilling was designed primarily to better define the high grade zones intercepted in the previous round of drilling and to facilitate a maiden JORC 2012 Mineral Resource estimate scheduled for delivery around end-Q1 2023.
A prior 52 hole, 5,353m RC drill program had extended the deposit's footprint to 2.5km north-south with several holes intercepting thick, multiple graphitic zones.
Palladium grades up to 7.06 g/t over one metre within a 33 metre high-grade intersection from new drill line 6,447,900.
Highest individual grades of copper and gold over one metre to date with 5.01 g/t 3E (1) (2.62 g/t Pd, 0.57 g/t Pt, 1.82 g/t Au), 1.96% copper, and 1.19% nickel within a high- grade 32 metre intersection on drill line 6,447,950.
33 metres @ 2.05 g/t 3E (1. 71 g/t Pd, 0.24 g/t Pt, 0. 10 g/t Au), 0.24% Cu & 0. 29% Ni from 271m.
ECS Botanics executes binding agreement with Ilios Sante GmbH to supply a minimum of AUD 9.9m worth of GMP manufactured, medicinal cannabis products over 3 years
German medicinal cannabis market continues to grow strongly, with German legislators recently moving to legalise recreational use
Ensuring that Ilios not only had the necessary narcotic licenses but also has its own clinic network, and the ability to adapt to future changes in cannabis legislation were key elements in securing the agreement.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has enrolled and randomised over 50% of the planned 154 patients in the TACTI -003 Phase IIb trial.
TACTI -003 is evaluating Immutep’s first-in-class soluble LAG-3 protein eftilagimod alpha (“efti”) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® as 1st line treatment of recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC).
Marc Voigt, CEO of Immutep stated: “We are pleased to reach this important milestone and extend our sincere appreciation to our investigators, clinical team, partners, and patients for their hard work and commitment to this study.”